Evaluation and comparison of the efficacy of triple therapies regimens containing esomeprazole and different doses of amoxicillin and bismuth for eradicating Helicobacter pylori infection in Sari

Phase 2

• Conditions: H. pylori infection.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20210518051335N1
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients have H. pylori eradication indication based on endoscopic evidence
Patients with positive Rapid urease test
Patients with positive histology of H. pylori infection

Exclusion Criteria

Age under 18 years
Reluctance to participate in the study
Pregnancy and lactation
Patients taking concomitant anticoagulants, corticosteroids or ketoconazole.
Patients with a history of gastric surgery
Patients with a history of heart failure, lung disease, chronic kidney failure, liver disease (cirrhosis or chronic hepatitis for any reason), or a history of cancer
Consumption of alcohol in any amount
The presence of any type of malignancy
History of drug allergy to the drugs in this study
History of H. pylori eradication regimens at any time before this study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
H. pylori eradication. Timepoint: At least the eighth week after starting treatment. Method of measurement: stool examination.

Secondary Outcome Measures

Name	Time	Method
Drug compliance rate. Timepoint: 8th week of study. Method of measurement: questionnaire.;Severity of drug side effects. Timepoint: 8th week of study. Method of measurement: questionnaire.